Facebook
X
LinkedIn
ForwardThis educational resource is intended to provide multidisciplinary medical teams and carers with an overview of the therapeutic area, information on guidelines, data from the latest clinical trials, and access to evidence based discussion that ensure patients receive a uniformly high standard of care with access to the latest available treatments for Alzheimer's Disease.
Video Introduction
Learning Activities
Advancing Knowledge of Disease-Modifying Treatments (DMTs)
Alzheimer's Disease Diagnosis
E-learning 2 – Alzheimer’s disease
The objective of this e-learning module is to strengthen knowledge of the Alzheimer's disease stages, the importance of early detection, and use of diagnostic biomarkers. The role of neuroimaging, amyloid-beta and tau pathology's complexities in AD are explored and treatment challenges discussed.
E-learning 1 – Alzheimer’s disease
The aim of the e-learning module is to improve the knowledge of Alzheimer's disease across the multidisciplinary healthcare team, to enhance understanding of the disease including its clinical presentation, screening, diagnosis and referral strategies for early AD to enable better patient outcomes.
Safe and Effective Use of Anti-Amyloid Therapies
Blood-Based Biomarkers in Alzheimer's Disease - An APAC Perspective
The diagnostic landscape for Alzheimer's disease is shifting fast. Blood-based biomarkers are moving from research curiosity to clinical reality, but adoption comes with real challenges. Join our webinar to hear directly from leading regional experts on what's clinically actionable today and what's coming next.
Navigating advances in Alzheimer's Disease: understanding and managing ARIA with anti-Aβ-amyloid therapies
In this webinar, Prof. Colin Masters, Dr. Masanori Kurihara and Prof. Mourad Tayebi explore disease-modifying therapies for Alzheimer's Disease (AD), with a focus on understanding and managing Amyloid-Related Imaging Abnormalities (ARIA). In the second part of the session, there was a peer-to-peer discussion. The discussion was moderated by Dr. Masanori Kurihara and the speakers address question…
Navigating Alzheimer's Disease: From Early Detection to Advanced Management
In the recent webinar, Prof. Ralph Martins and Prof. Yuan-Han Yang, with moderator Prof. Vincent Mok, delivered a comprehensive session covering the identification of Alzheimer's disease signs, symptoms, and differential diagnosis. The discussion explored the role of biomarkers in early detection and the latest advancements in imaging and fluid biomarkers. The speakers analysed the current therap…
Understanding Clinical Meaningfulness in Alzheimer’s Disease Care: A Guide for Health Care Professionals
Session Highlights In a recent webinar, Prof. Jacqueline C. Dominguez, Prof. Atsushi Iwata, and Prof. Christopher Chen, moderated by Dr. Masanori Kurihara, delivered a comprehensive session on clinical meaningfulness in Alzheimer's Disease. The session concluded with a live Q&A, allowing participants to engage directly with these leading experts. Prof. Jacqueline C. Dominguez explored the var…
Example Webinar
UPCOMING WEBINAR - REGISTER NOW! Blood-Based Biomarkers in Alzheimer's Disease - An APAC Perspective
REGISTER NOW! The diagnostic landscape for Alzheimer's disease is shifting fast. Blood-based biomarkers are moving from research curiosity to clinical reality, but adoption comes with real challenges. Join our webinar to hear directly from leading regional experts on what's clinically actionable today and what's coming next.
Supplementary Materials
Blood-Based Biomarker in Alzheimer's Disease: From Diagnosis to Follow-Up
• Prevalence and advancements in the Asia-Pacific region • Biological confirmation of AD supported by BBM • Alzheimer's Association Clinical Practice Guidelines for BBM tests • AD treatment planning: decision and initiation • Patient-specific factors that may affect the selection of biomarker modality • Post-treatment monitoring and follow-up for AD using BBM • Clinical questions addressed
Detection and Management of Amyloid-Related Imaging Abnormalities During Alzheimer’s Disease Treatment
• Challenges in detecting ARIA clinically • Clinical progression of ARIA • Standard MRI protocol for ARIA detection • Anti-amyloid therapy and ARIA • Strategies for managing ARIA and the role of healthcare professionals
Mapping the Future: Disease-Modifying Treatments for Alzheimer’s
Our infographic reveals how Disease-Modifying Therapies (DMTs) are revolutionizing Alzheimer's Disease care. It highlights the urgent need for novel biomarkers that enable non-invasive, high-throughput detection of pre-symptomatic AD, significantly enhancing diagnostic capabilities. The infographic also emphasizes the importance of education and training in establishing new care pathways, ensurin…
Navigating Alzheimer's Disease
Explore our infographic on Alzheimer's disease diagnosis and care. Learn about symptoms, differential diagnosis, and criteria, with a spotlight on biomarkers and imaging. Further your knowledge about amyloid-targeted therapies for early AD, managing Amyloid-Related Imaging Abnormalities (ARIA), and current treatment guidelines for comprehensive patient support.
Overview of disease continuum and early diagnosis
• Outline of clinical stages associated with AD. • AD continuum and pathophysiological changes associated with AD progression. • Emphasizes the need and barriers of early diagnosis of AD.
Pathway to Accurate Alzheimer's Diagnosis
Pathway to Accurate Alzheimer's Diagnosis
The Current Treatment Landscape of Alzheimer's Disease
• Understanding the clinically meaningful benefits of treatments for Alzheimer’s disease (AD) • Monoclonal antibodies targeting amyloid β in AD • Collaborative and equitable dementia care • Prevention potential of AD
Example Infographic
Infographic Post
Meet the Faculty
Prof. Ralph Martins
Professor of Neurobiology at Macquarie University in Sydney Foundation Professor of Ageing and Alzheimer's Disease at Edith Cowan University in Perth
Associate Prof. Nagaendran Kandiah
Associate Professor of Neuroscience, Lee Kong Chian School of Medicine Associate Professor, Lee Kong Chian School of Medicine
Prof. Christopher Chen Li-Hsian
Professor, Yong Loo Lin School of Medicine, National University of Singapore
Senior Clinician-Scientist at the Yong Loo Lin School of Medicine, National University of Singapore,Dr Chen is a Professor and Senior Clinician-Scientist at the Yong Loo Lin School of Medicine, National University of Singapore, supported by a Singapore Translational Research Investigator Award from the National Medical Research Council of Singapore.He trained at Cambridge, Oxford and the Institute of Neurology, London. His major research and clinical interests are in blood biomarkers, neuroimaging and treatment of stroke and dementia. He has published over 500 peer-reviewed papers, leads studies on the treatment and prevention of stroke and dementia, and is a member of trial steering and safety committees. As Director of the Memory Aging and Cognition Centre he has supervised over 40 post-graduate students, and by co-chairing the World Stroke Organisation's Future Leaders Program he mentors young academics and clinicians globally.
Prof. Masafumi Ihara, MD, PhD, FACP, FAHA
Director, Department of Neurology, National Cerebral and Cardiovascular Center (NCVC), Osaka, Japan Director, Department of CADASIL Research and Development
Dr Masafumi Ihara, MD, PhD, FACP, FAHA is Director, Department of Neurology, National Cerebral and Cardiovascular Center (NCVC), Osaka, Japan (2013-present). He is also Director, Department of CADASIL Research and Development, NCVC (2025-present). He graduated from Kyoto University School of Medicine in 1995. He received clinical training at Kyoto University Hospital in 1995 and Nishi-Kobe Medical Center in 1995-1999. In 1999 he entered Kyoto University Graduate School of Medicine and completed a PhD in Neuroscience in 2003. He received his neuropathological training under supervision of Prof. Kalaria in Newcastle University, UK during 2006-2008. He led a neurovascular research group as an assistant professor of Department of Neurology in Kyoto University (2008-2012) and as a deputy director of Department of Regenerative Medicine Research in Institute of Biomedical Research and Innovation (IBRI), Kobe (2012-2013). His research interests have focused on the pathological changes in brain blood vessels and how the alterations impact on brain health during old age. He is a Fellow of the Japanese Society of Neurology, the American Heart Association (FAHA), and the American College of Ph
Prof. So Yeon Jeon, MD, PhD
Professor of Psychiatry at Seoul National University Boramae Medical Center, where I lead the antiamyloid antibody treatment program.
Associate Professor Paul Yates
Consultant Geriatrician Director of Research and Medical Lead, Memory Clinic Deputy Head of Unit, Geriatric Medicine Austin Health Clinical Associate Professor Department of Medicine, Austin Health University of Melbourne
Guest Speakers
Dr. Jacqueline Dominguez
Head, Memory Center, St. Luke's Medical Center - Global City
Dr. Jacqueline Dominguez is a neurologist with a special interest in aging and cognitiveimpairment. She graduated from the St. Louis University College of Medicine and trained in Adult Neurology at the St. Luke's Institute for Neurosciences. Her interestin dementia made her pursue training in Alzheimer's Disease and Related Disorders at Washington University in St. Louis, MO. She now heads the St.Luke's Memory Center. Dr. Dominguez is a long-time advocate for dementia care not only in its medical but sociocultural aspects. As an anthropologist, her research interest includes underpinnings of culture and dementia care, one of which is the urban communitybased Marikina Memory and Aging Project to develop community and family-based non-pharmacologic interventions in dementia.
Professor Colin Masters AO
Professor The Florey Institute, The University of Melbourne
Dr. Atsushi Iwata
M.D, Ph.D. Professor, Tokyo Metropolitan Institute for Geriatrics and Gerontology
Dr. Iwata received his M.D. and Ph.D. from the University of Tokyo. He completed postdoctoral training at Stanford University by studying autophagy and neurodegeneration. Now a senior assistant professor and Director of outpatient clinic at the University of Tokyo Hospital, he serves as a general neurologist as well as behavioral neurologist at the memory clinic. His current research aims to elucidate pathomechanisms of sporadic neurodegenerative disorders through epigenetics and molecular biology. He is also conducting various clinical studies and serves as clinical core of Japanese ADNI studies.
Dr. Masanori Kurihara
Doctor, Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan
Dr. Masanori Kurihara received his medical degree from the University of Tokyo. After completing medical training and neurology residency, he became a board-certified neurologist by the Japanese Society of Neurology. He then joined the Graduate School of Medicine at the University of Tokyo. He was elected as a research fellow (DC2) of the Japanese Society for the Promotion of Science, and has received several public research grants since then. His thesis was "Investigation of tau-induced aggregation of BRCA1 in tauopathies". After receiving Ph.D., he moved to Tokyo Metropolitan Institute for Geriatrics and Gerontology and serves as a general neurologist and as a board-certified dementia specialist by Japan Society for Dementia Research.
Prof. Ming-Chyi Pai
Professor of Neurology and the Director of the Institute of Gerontology at National Cheng Kung University (NCKU)
Professor Ming-Chyi Pai is also the Director and Principal Investigator of the Alzheimer's Disease Research Center (ADRC) at NCKU Hospital, where he has been conducting many global clinical trials on AD and related dementias. Prof. Pai graduated from Taipei Medical University (M.D.) in 1988 and obtained his Ph.D. degree (psychology) from National Chung Cheng University in 2002. Dr. Pai studied neuropsychology at Tohoku University from 1995 to 1996 and studied psychology at the University of Arizona from 2002-2003. His major interests are cognitive and behavioural neurology, in particular human spatial navigation as a maker for Alzheimer disease and using AI to help diagnose and classify different types of neurodegenerative disorders.
External Supplementary Resources
External Resources (215 links) — click to expand
- 2023 Alzheimer's disease facts and figures
- A Systematic Review of Clinical Practice Guidelines for Alzheimer’s Disease and Strategies for Future Advancements
- Consensus statement on the use of Alzheimer's disease biomarkers and anti-amyloid therapies in Hong Kong
- A call for clinical trial globalization in Alzheimer's disease and related dementia
- A Call for Improving Clinical and Cognitive Assessments to Reduce the Gap Between Amyloid/Tau Pathology Onset and Detection of Cognitive Dysfunction
- A deep learning model for detection of Alzheimer's disease based on retinal photographs: a retrospective, multicentre case-control study
- A Framework for Best Practices and Readiness in the Advent of Anti-Amyloid Therapy for Early Alzheimer’s Disease in Asia
- A point-based cognitive impairment scoring system for southeast Asian adults
- A qualitative study investigating clinician experiences with lecanemab implementation across seven academic medical centers
- A regional framework for the detection and management of ARIA with anti-amyloid therapies in early Alzheimer's disease in Asia
- Accelerated 3D MRI for ARIA monitoring in Alzheimer's disease
- Access to preferred skilled nursing facilities: Transitional care pathways for patients with Alzheimer's disease and related dementias
- ADNI Biomarker Core: A review of progress since 2004 and future challenges
- Aducanumab: Appropriate Use Recommendations Update
- Age and sex differences in the association between APOE genotype and Alzheimer’s disease in a Taiwan Chinese population
- Alzheimer disease
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care
- Alzheimer's disease
- Alzheimer's disease diagnosis and management: Perspectives from around the world
- Alzheimer’s Disease: Epidemiology and Clinical Progression
- Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs
- Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney
- Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future
- Amyloid-β but not tau accumulation is strongly associated with longitudinal cognitive decline
- Amyloid-related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid-modifying therapy
- Amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease: from pathophysiology to individualized risk assessment
- Amyloid-related imaging abnormalities (ARIA) in Alzheimer's immunotherapy: a framework and challenges for global surveillance strategies
- Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup
- Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
- Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
- Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study
- Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease
Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials - Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist
- Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline
- Anti-amyloid therapies for Alzheimer disease: finally, good news for patients
- APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry
- Application of blood-based biomarkers of Alzheimer's disease in clinical practice: Recommendations from Taiwan Dementia Society
- ARIAs are not random: A posterior and border-zone vascular vulnerability model
- Assessment of High Risk for Alzheimer’s Disease Using Plasma Biomarkers in Subjects with Normal Cognition in Taiwan: A Preliminary Study
- Association between amyloid, tau and cerebral small vessel disease
- Association Between Plasma GFAP and Medial Temporal Atrophy and Cognition in Amyloid-Negative Cerebrovascular Disease
- ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab
- Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab
- Biomarker changes associated with fornix deep brain stimulation in Alzheimer's disease
- Biomarkers in Alzheimer's disease clinical trials: 2025
- Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants
- Biomarkers of Alzheimer's disease pathophysiology and delirium
- Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
- Blood-based biomarkers of Alzheimer’s disease and incident dementia in the community
- Blood-based multimodal biomarker models for differentiating early-onset Alzheimer's disease from frontotemporal dementia: a longitudinal study of early-onset dementia and family members (LEAF) study
- Blood biomarkers for Alzheimer’s disease in clinical practice and trials
- Blood Biomarkers of Alzheimer’s Disease and Cognition: A Literature Review
- Blood Pressure Variability and the Risk of Dementia: A Nationwide Cohort Study
- Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging
- Care Ecosystem Collaborative Model and Health Care Costs in Medicare Beneficiaries With Dementia: A Secondary Analysis of a Randomized Clinical Trial
- Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease
- Challenges and progress in research, diagnostics, and therapeutics in Alzheimer's disease and related dementias
- Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease
- Characteristics of infusion-related reactions to lecanemab in early Alzheimer's disease: A multicenter real-world study in Northwestern China
- Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease
- Clinical meaningfulness of anti-amyloid therapies in early Alzheimer's disease: Perspectives from the East and Southeast Asia region
- Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
- Clinical utility of plasma p-tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease
- Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials
- Combining Lumipulse p-tau217 and Aβ42/40 as confirmatory tests for Aβ positivity prior to disease-modifying therapy
- Communicating with patients about the new disease-modifying treatment(s) for Alzheimer’s disease: the perspective of memory clinic professionals
- Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis
- Comparative efficacy and safety of symptomatic therapy and disease-modifying therapy for Alzheimer’s disease: a systematic review and network meta-analysis
- Comparing machine learning-derived MRI-based and blood-based neurodegeneration biomarkers in predicting syndromal conversion in early AD
- Comparison of plasma p-tau217/Aβ42, p-tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease
- Consensus statement on the use of Alzheimer's disease biomarkers and anti-amyloid therapies in Hong Kong
- Consensus statement on the use of Alzheimer's disease biomarkers and anti-amyloid therapies in Hong Kong
- Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review
- Contextualising the benefits and risks of anti-amyloid therapy for patients with Alzheimer disease and their care team
- Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications
- Current and Future Trends in Biomarkers for the Early Detection of Alzheimer’s Disease in Asia: Expert Opinion
- Current status and future directions for the diagnosis and management of mild cognitive impairment in Southeast Asia: A SEACURE consensus paper
- Deciphering the A–T+ enigma: Clinical relevance or diagnostic noise?
- Dementia diagnostic and treatment services in the Western Pacific: challenges, preparedness and opportunities in the face of amyloid-targeting therapies
- Dementia diagnostic and treatment services in the Western Pacific: challenges, preparedness and opportunities in the face of amyloid-targeting therapies
- Designing the next-generation clinical care pathway for Alzheimer’s disease
- Detection and treatment of Alzheimer’s disease in its preclinical stage
- Development of disease-modifying therapies against Alzheimer's disease
- Distinguishing Alzheimer’s disease from other major forms of dementia
- Donanemab: Appropriate use recommendations
- Donanemab therapy in Alzheimer’s disease with mild cognitive impairment: Convergent amyloid, tau, and plasma biomarker normalization with cognitive improvement
- Drug repurposing in Alzheimer's disease: Emerging therapeutic strategies and promising candidates
- Early-stage Alzheimer disease: getting trial-ready
- Effectiveness of Early Multimodal Non-pharmacological Interventions in Cognitive Preservation in the Elderly
- Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study
- Efficacy and safety of blood derivatives therapy in Alzheimer’s disease: a systematic review and meta-analysis
- Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer’s disease: A systematic review and meta-analysis
- Efficacy, safety, and ARIA risk of anti-β-amyloid antibodies in early Alzheimer's disease: a systematic review, meta-analysis, and meta-regression
- Eligibility for amyloid targeting therapies among primary care patients with cognitive symptoms
- Eligibility for Anti-Amyloid-β Monoclonal Antibodies in Patients With Primary Progressive Aphasia due to Alzheimer's Disease in Japan
- Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer’s disease
- Eligibility for lecanemab therapy in a biomarker defined memory clinic cohort: A five-year analysis
- Eligibility for lecanemab treatment in a French memory clinic setting
- Eligibility for Lecanemab Treatment in the Republic of Korea: Real-World Data From Memory Clinics
- Emerging diagnostics and therapeutics for Alzheimer disease
- Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment
- Ethical issues when using digital biomarkers and artificial intelligence for the early detection of dementia
- Evaluation of clinical benefits of treatments for Alzheimer's disease
- Evaluation of major national dementia policies and health-care system preparedness for early medical action and implementation
- Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort
- Evidence of plasma biomarkers indicating high risk of dementia in cognitively normal subjects
- Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent
- Female reproductive factors and the risk of dementia: a nationwide cohort study
- Gender differences in presentation of behavioral and psychological symptoms in Alzheimer’s disease in Taiwan
- Generalizability of blood-based biomarkers of Alzheimer's disease and related dementias in a multicultural cohort of older adults: The effect of adjustment for kidney function
- Have I Been Here? Sense of Location in People With Alzheimer's Disease
- Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
- Health system patterns of imaging and fluid biomarker testing in the era of anti-amyloid therapies
- In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences
- Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti–β-Amyloid Immunotherapy
- Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy
An Updated Meta-Analysis - Incipient symptoms of Alzheimer's disease and effect of education on the onset age: A study of 155 Taiwanese patients
- Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's disease
- Initial real-world experience with lecanemab prescribing patterns in Japan: The Longevity Improvement & Fair Evidence (LIFE) Study
- Integrating neuroinflammation biomarkers into the ATN(X) framework: Advances in Alzheimer's pathogenesis, diagnosis, and insights from non-human primate models
- Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study
- Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer’s disease
- Is the risk of developing Alzheimer's disease really higher in rural areas? A multilevel longitudinal study of 261,669 Australians aged 45 years and older tracked over 11 years
- Lecanemab: Appropriate Use Recommendations by Korean Dementia Association
- Multimodal Precision Prevention - A New Direction in Alzheimer’s Disease
- Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes
- Lecanemab over a two-year duration: Key insights from a regional specialty medical center
- Lecanemab treatment improves B cell subpopulation immune homeostasis in patients with Alzheimer's disease
- Long-term treatment of early Alzheimer's disease with donanemab
- Machine Learning-Derived MRI-Based Neurodegeneration Biomarker for Alzheimer’s Disease: A Multi-Database Validation Study
- Memory Consolidation and ARIA in Individuals Receiving Anti-amyloid Monoclonal Antibodies
- Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real-word study on aducanumab and lecanemab
- Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives
- Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction
- Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights
- MRI-based Alzheimer’s disease-resemblance atrophy index in the detection of preclinical and prodromal Alzheimer’s disease
- Multicenter validation of plasma p-tau217/ amyloid beta 1-42 ratio in symptomatic Alzheimer's disease
- New approaches to symptomatic treatments for Alzheimer’s disease
- Novel Monoclonal Antibody Detects Small Aβ Oligomers More Sensitively Than Lecanemab in Alzheimer's Disease CSF, Serum and Culture Media
- Olfactory Impairment and Incident Cognitive Decline: A Systematic Review and Meta-Analysis
- Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease
- People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare
- Plasma brain-derived p-Tau217 outperforms other p-Tau species in detecting abnormal brain amyloid in an Asian cohort of older people with cerebrovascular disease burden
- Plasma pTau 217/β-amyloid 1–42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology
- Plasma p‐tau217 predicts PET‐based pathological staging for precision Alzheimer disease assessment
- Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease
- Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease
- Practical Brain MRI Guidelines for Anti-Aβ Antibody Treatment in Early Symptomatic Alzheimer’s Disease
- Practical Guide of the Korean Association for Geriatric Psychiatry to Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Focused on Lecanemab
- Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis
- Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis
- Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment
- Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
- Predictive Ability of Plasma p-tau217 for β-Amyloid Status: A Prospective Multicenter Study
- Preparing for disease-modifying dementia therapies in the UK
- Preparing for disease-modifying therapies in Alzheimer's disease
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
- Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment
- Rational Use of Blood-Based Biomarkers for Alzheimer's Disease: Navigating Between the Hope and the Hype
- Real world clinical practice of lecanemab at PUMCH dementia cohort: focus on dynamic imaging and biomarker evolution
- Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience
- Real-world safety and implementation challenges of lecanemab therapy for Alzheimer's disease in South Korea: a single-center experience
- Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
- Regulatory, clinical, and post-marketing challenges of lecanemab for Alzheimer's disease: insights from real-world data
- Rethinking the detection and diagnosis of Alzheimer’s disease: Outcomes of a European Brain Council project
- Retinal imaging in Alzheimer’s disease
- Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
- Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective
- Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
- Screening for Alzheimer's disease in the community using an AI-driven screening platform: design of the PREDICTOM study
- Severe symptomatic amyloid-related imaging abnormalities in Alzheimer's disease: Two case reports and systematic review of reported cases
- Six-month follow-up of ARIA-H and iron deposition in real-world lecanemab therapy for Alzheimer's disease: Evidence from a Chinese 7T MRI cohort
- Spotlight on Alzheimer's disease and related dementias research in East Asia
- Successful Amyloid Removal by Donanemab Treatment in a Female Patient With Alzheimer Disease: A Case Report
- System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment
- The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease
- The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention
- The Incidence and Recurrence of Getting Lost in Community-Dwelling People with Alzheimer’s Disease: A Two and a Half-Year Follow-Up
- The National Institute on Aging - Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials
- The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer’s disease
- The patient pathway for mild cognitive impairment due to Alzheimer’s disease in Asia: Current practices, barriers, and expert recommendations for optimization
- Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer’s disease
- Therapeutic time window of disease-modifying therapy for early Alzheimer's disease
- Therapeutic time window of disease-modifying therapy for early Alzheimer's disease
- Topographical disorientation in community-residing patients with Alzheimer's disease
- Ultra-fast MRI for dementia diagnosis and treatment eligibility: A prospective study
- Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research
- Ushering in a New Era of Alzheimer Disease Therapy
- Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease
- A Comprehensive Approach to Alzheimer's Diagnosis
- AAIC 2024 Conference Highlights
- Alzheimer's Association International Conference (AAIC) 2025
- Advancing Knowledge of Disease-Modifying Treatments (DMTs)
- Anti-Amyloid Therapy for Early Alzheimer’s: ARIA Management
- ARIA Management in Real-World Practice: From Evidence to Multidisciplinary Care in APAC
- Blood-Based Biomarkers in Alzheimer's Disease: A Case Study on Diagnosis and Post-Treatment Monitoring in APAC
- Bridging the Gap: Standardizing Alzheimer's Diagnostic Practices
- Diagnostic processes and treatment strategies for mild cognitive impairment and Alzheimer's Disease
CASE STUDY - Decoding Alzheimer's Disease: Exploring Risk Factors, the ATN Framework, and Treatment Strategies
VIDEO ABSTRACT - Collaborative Care in Managing ARIA
- Clinical Trials on Alzheimer's Disease (CTAD) Congress 2024
- Disease-Modifying Treatments (DMTs) in Alzheimer’s Disease
- Enhancing Diagnostic Proficiency in Alzheimer’s Disease
- Ensuring Safe and Effective Use of Anti-Amyloid Therapies: A Multidisciplinary Perspective
- Expert Commentary with Professor Yuan-Han Yang
- Key elements in understanding Alzheimer's Disease:
Prevalence, Etiology, Risk Factors, and Biological Definitions
KOL COMMENTARY - Navigating Treatment Options in Alzheimer's Disease
- Operationalizing blood biomarkers across the care continuum
- Peer to peer discussion on Alzheimer’s disease (AD)
- Professor Masters – A Follow Up to CTAD
- Signs and symptoms of Alzheimer’s disease, diagnostic challenges and treatment approaches
- Treating Beyond the Trial: Three Decisions in Anti-Amyloid Therapy and ARIA